Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

Inclusion Criteria: * "Definite MS" as defined by revised McDonald criteria. * Bilateral distal symmetric burning pain involving both feet for at least three months. * Baseline weekly average pain rating equal to four or greater on 0-10 numerical scale. * Stable MS medication and pain-related medications for 8 weeks prior to screening. * Must come to Research Center for appointments Exclusion Criteria: * Topical treatment with lidocaine, capsaicin, or other topical analgesics within 3 months prior to screening. * Any treatment with opioid analgesics or tramadol within 3 months prior to screening. * Hypersensitivity to Lidoderm, lidocaine, or other local anesthetics. * Hypersensitivity or inability to tolerate opioid analgesics. * Current treatment with a total of 3 or more antidepressant or anticonvulsant drugs for pain. * Current treatment with Class I anti-arrhythmic agents at baseline. * Beck Depression Inventory score \> 16 or clinically significant depression or dementia. * History of suicide attempt or current intent or plan. * History of excessive alcohol use or any illicit drug use within the past 2 years. * Lack of adequate birth control in pre-menopausal women of childbearing age. * Other pain more severe than lower extremity burning pain. * Open skin lesions in the area where the lidocaine patch is to be applied. * Cancer within the previous 5 years other than skin cancer. * MS exacerbation or any treatment with corticosteroids within 3 months prior to screening. * History of peripheral neuropathy, lower limb amputation, or another neuromuscular syndrome or systemic disorder known to be associated with sensory neuropathy. * Does not meet criteria of baseline lab values at screening visit. * Nerve conduction studies consistent with peripheral neuropathy.